Defence Therapeutics (XCNQ:DTC) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Defence Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Defence Therapeutics ROCE % Historical Data

The historical data trend for Defence Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics ROCE % Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

ROCE %

-36.11

-77.79

-287.06

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-	-	-380.73	-402.97	-

Defence Therapeutics ROCE % Calculation

Defence Therapeutics's annualized ROCE % for the fiscal year that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2022 )		(A: Jun. 2021 )		(A: Jun. 2022 )
	=	-7.32	/	( ( (5.609 - 0.122)	+	(0.72 - 1.107) )	/ 2 )
	=	-7.32	/	( (5.487	+	-0.387)	/ 2 )
	=	-7.32	/	2.55
	=	-287.06 %

Defence Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-33.048	/	( ( (1.588 - 0.391)	+	(0.669 - 2.942) )	/ 2 )
	=	-33.048	/	( ( 1.197	+	-2.273 )	/ 2 )
	=	-33.048	/	-0.538
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Defence Therapeutics (XCNQ:DTC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Defence Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.